

Marinomed Biotech AG

27.01.2020 – 14:00 Uhr

EANS-Voting Rights: Marinomed Biotech AG / Publication of a participation notification according to art. 135 para. 2 Stock Exchange Act

Notification of voting rights transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement.

Overview

1. Issuer: Marinomed Biotech AG

2. Reason for the notification: Acquisition or disposal of voting rights

3. Person subject to notification obligation

Acting in concert (Sec. 133 No. 7 BörseG 2018)

First name	Name/Surname	City	Country
Abdulmohsen	Al Sheikh		
Mohammed	Al Sheikh		
Acropora Beteiligungs GmbH		Vienna	Austria

4. Name of shareholder(s):

5. Date on which the threshold was crossed or reached: 22.1.2020

6. Total positions:

	% of voting rights through	% of voting rights attached to shares (7.A)	financial/other instruments (7.B.1 + 7.B.2)	Total of both in % (7.A + 7.B)	Total number of voting rights of issuer
Resulting situation on the date on which threshold was crossed / reached	16.59 %	0,00 %	16.59 %	1,469,772	
Position of previous notification (if applicable)	23.27 %	0,00 %	23.27 %		

Details

7. Notified details of the resulting situation:

A: Voting rights attached to shares					
Number of voting rights		% of voting rights			
Direct	Indirect (Sec 130 BörseG 2018)	Direct	Indirect (Sec 130 BörseG 2018)		
ISIN Code AT0000831706	(Sec 130 BörseG 2018)	133 BörseG 2018	(Sec 130 BörseG 2018)	133 BörseG 2018	
243,860		16.59 %			

----- ----- ----- ----- -----			
SUBTOTAL A	243,860	16.59%	
----- ----- ----- ----- -----			

B 1: Financial / Other Instruments pursuant to Sec. 131 para. 1 No. 1				
BörseG 2018				

			Number of voting	
			rights that may	
Type of			be acquired if	% of voting
instrument	Expiration Date	Exercise Period	the instrument is	rights
			exercised	
-----	-----	-----	-----	-----
-----	-----	-----	-----	-----
		SUBTOTAL B.1		
-----	-----	-----	-----	-----

B 2: Financial / Other Instruments pursuant to Sec. 131 para. 1 No. 2				
BörseG 2018				

	Expiration	Exercise	Physical / Cash	Number of
Type of	Date	Period	Settlement	% of voting
instrument	-----	-----	-----	-----
-----	-----	-----	-----	-----
		SUBTOTAL B.2		
-----	-----	-----	-----	-----

8. Information in relation to the person subject to the notification obligation:
Full chain of controlled undertakings through which the voting rights and/or the financial/other instruments are effectively held starting with the ultimate controlling natural person or legal entity:

			Financial/	
			Directly	other
			controlled	Shares held
	No.	Name	by No.	instruments
			directly (%)	held directly
			(%)	(%)
-----	-----	-----	-----	-----
		Abdalmohsen		
	1	Al Sheikh		
-----	-----	-----	-----	-----
		Mohammed Al		
	2	Sheikh		
-----	-----	-----	-----	-----
		Acropora		
	3	Beteiligungs	1,2	16.59 %
		GmbH		16.59 %
-----	-----	-----	-----	-----

9. In case of proxy voting
Date of general meeting: -
Voting rights after general meeting: - is equivalent to - voting rights.

10. Additional comments:
The disclosure obligation arose because the number of shares held dropped below the threshold due to the sale of 73,500 shares.

Further inquiry note:
Dr. Eva Prieschl-Grassauer
Chief Scientific Officer, Marinomed

Veterinärplatz 1, 1210 Vienna, Austria
T +43 (0)1 250 77 4460
E-Mail: eva.prieschl@marinomed.com
<http://www.marinomed.com>

Roland Mayrl
Managing Partner, Metrum Communications
Bauernmarkt 10/19, 1010 Vienna, Austria
T +43 (0) 1 504 69 87 331
E-Mail: r.mayrl@metrum.at
<http://www.metrum.at>

end of announcement euro adhoc

issuer: Marinomed Biotech AG
 Veterinärplatz 1
 A-1210 Wien
phone: 0043250774460
FAX: 0043250774493
mail: office@marinomed.com
WWW: www.marinomed.com
ISIN: ATMARINOMED6, AT0000A1WD52
indexes:
stockmarkets: Wien
language: English

Original content of: Marinomed Biotech AG, transmitted by news aktuell
Diese Meldung kann unter <https://www.presseportal.de/en/pm/132651/4503692> abgerufen werden.